Previously unpublished trial data explain effects and side effects of key MS drug

Alemtuzumab is a highly effective drug for multiple sclerosis, approved in more than 60 countries and used by more than 12,000 patients worldwide. However, there is an almost 50 per cent risk of secondary autoimmune diseases, some of which are life-threatening, such as platelet and kidney diseases.

Although knowledge about these adverse effects was included in conference presentations and licensing submissions to European and US regulators, critical data to explain secondary autoimmune disease had not been scrutinised and published following peer review.

Through a Freedom of Information request to the…

Favicon of www.medicalnewstoday.com da : www.medicalnewstoday.com

Prosegui la lettura...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati

Pubblicità

Pubblicità